Effect of delayed‐release dimethyl fumarate on no evidence of disease activity in relapsing–remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies

BACKGROUND AND PURPOSE: Significant effects on clinical/neuroradiological disease activity have been reported in patients with relapsing–remitting multiple sclerosis treated with delayed‐release dimethyl fumarate (DMF) in phase III DEFINE/CONFIRM trials. We conducted a post hoc analysis of integrate...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Eur J Neurol
Huvudupphovsmän: Havrdova, E., Giovannoni, G., Gold, R., Fox, R. J., Kappos, L., Phillips, J. Theodore, Okwuokenye, M., Marantz, J. L.
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2017
Ämnen:
Original Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5413827/
https://ncbi.nlm.nih.gov/pubmed/28328179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ene.13272
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk